PIPELINE
What we develop
Nuravax Is on a Trajectory of Significant Growth and Advancement
Our pipeline includes six programs targeting Alzheimer's, tauopathies (including CTE/rTBI), and α-synucleinopathies (including Parkinson’s disease), supported by primarily non-dilutive funding. Two programs have completed Phase 1 dosing, and by the end of 2025, we plan to secure FDA clearance for two additional INDs.
Current Status of IND / pre-IND products (vaccines)
1
2
3
4
CANDIDATE
DISCOVERY
PRE-CLINICAL STUDIES
SAFETY / TOXICOLOGY
IND
PHASE 1
PHASE 2
PHASE 3
AV-1959D
(Abeta DNA vaccine)
(Abeta DNA vaccine)
AV-1980R
(Tau Recom vaccine)
(Tau Recom vaccine)
AV-1959R
(Abeta Recom vaccine)
(Abeta Recom vaccine)
Duvax
Phase 1: Enrollment & Treatment Completed
Phase 1: Enrollment & Treatment Completed
5
PV-1950
(Parkinson's disease)
(Parkinson's disease)
IND Cleared
6
AV-1959LR
mRNA
mRNA
Our non-clinical trials have yielded encouraging results. Vaccinating transgenic animal models with our amyloid beta peptide (Aβ), tau, and ɑ-synuclein vaccines produced high antibody titers and resulted in a substantial reduction of Aβ plaques, tau tangles, and oligomers. These vaccines also reduced the activation of microglia and astrocytes without increasing microhemorrhages.
Animals vaccinated with MultiTEP vaccines additionally generated more antibodies than animals vaccinated with other immunotherapies currently in clinical trials. These findings highlight potential advantages of Nuravax vaccines in the treatment of neurodegenerative conditions.
Animals vaccinated with MultiTEP vaccines additionally generated more antibodies than animals vaccinated with other immunotherapies currently in clinical trials. These findings highlight potential advantages of Nuravax vaccines in the treatment of neurodegenerative conditions.
Promising Non-Clinical Trial Outcomes